Restricted accessResearch articleFirst published online 2022-8
MDMA-assisted therapy for posttraumatic stress disorder: A pooled analysis of ethnoracial differences in efficacy and safety from two Phase 2 open-label lead-in trials and a Phase 3 randomized,blinded placebo-controlled trial
Limited ethnoracial diversity in previous ±3,4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT) trials for posttraumatic stress disorder (PTSD) has prompted questions concerning whether Black, Indigenous, and People of Color (BIPOC) also benefit from this treatment.
Methods:
Secondary analysis was conducted using a modified intent-to-treat sample pooled from two Phase 2 open-label trials and a Phase 3 randomized, blinded placebo-controlled trial to compare efficacy and safety of MDMA-AT for PTSD between BIPOC and non-Hispanic White participants. Four subgroups were of interest: MDMA-AT, BIPOC (n = 20); MDMA-AT, non-Hispanic White (n = 63); Placebo-assisted therapy (Placebo-AT), BIPOC (n = 17); and Placebo-AT, non-Hispanic White (n = 27). Planned comparisons tested subgroup differences in changes in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) scores from baseline to primary endpoint, controlling for study type and baseline scores. Adverse events (AEs) on the day of (day 0) to 2 days post-dosing were reported for each subgroup.
Results:
In the MDMA-AT group, no significant ethnoracial difference in CAPS-5 change scores was observed. In the Placebo-AT group, BIPOC participants trended toward greater reductions in CAPS-5 scores than non-Hispanic Whites. Among non-Hispanic Whites, MDMA-AT was accompanied by significantly greater reductions in CAPS-5 scores than Placebo-AT. No treatment difference emerged among BIPOC participants. AEs were mostly rated as mild or moderate across subgroups.
Conclusions:
These findings provide preliminary support for the efficacy and safety of MDMA-AT for treating PTSD across ethnoracial groups. There was also a trend toward greater efficacy with Placebo-AT among BIPOC participants. There was an imbalance in subgroups, highlighting the need for culturally responsive recruitment strategies to diversify future studies.
AlegríaMFortunaLRLinJY, et al. (2013) Prevalence, risk, and correlates of posttraumatic stress disorder across ethnic and racial minority groups in the United States. Med Care51: 1114–1123.
2.
AlimTNCharneyDSMellmanTA (2006) An overview of posttraumatic stress disorder in African Americans. J Clin Psychol62: 801–813.
3.
BenítezCIPSibravaNJKohn-WoodL, et al. (2014) Posttraumatic stress disorder in African Americans: A two-year follow-up study. Psychiatry Res220: 376–383.
4.
BershadAKMillerMABaggottMJ, et al. (2016) The effects of MDMA on socio-emotional processing: Does MDMA differ from other stimulants?J Psychopharmacol30: 1248–1258.
5.
BissonJIRobertsNPAndrewM, et al. (2013) Psychological therapies for chronic post-traumatic stress disorder (PTSD) in adults. Cochrane Database Syst Rev2013: CD003388.
6.
ChingTHW (2020) Intersectional insights from an MDMA-assisted psychotherapy training trial: An open letter to racial/ethnic and sexual/gender minorities. J Psychedelic Stud4: 61–68.
7.
ChingTHWLeeSYChenJ, et al. (2018) A model of intersectional stress and trauma in Asian American sexual and gender minorities. Psychol Violence8: 657–668.
8.
De las CuevasCMotucaMBaptistaT, et al. (2018) Skepticism and pharmacophobia toward medication may negatively impact adherence to psychiatric medications: A comparison among outpatient samples recruited in Spain, Argentina, and Venezuela. Patient Prefer Adherence12: 301–310.
FeducciaAAMithoeferMC (2018) MDMA-assisted psychotherapy for PTSD: Are memory reconsolidation and fear extinction underlying mechanisms?Prog Neuropsychopharmacol Biol Psychiatry84: 221–228.
11.
FeenyNCZoellnerLAKahanaSY (2009) Providing a treatment rationale for PTSD: Does what we say matter?Behav Res Ther47: 752–760.
12.
GabayASKemptonMJGilleenJ, et al. (2019) MDMA increases cooperation and recruitment of social brain areas when playing trustworthy players in an iterated prisoner’s dilemma. J Neurosci39: 307–320.
13.
GeorgeJRMichaelsTISeveliusJ, et al. (2020) The psychedelic renaissance and the limitations of a White-dominant medical framework: A call for indigenous and minority inclusion. Journal of Psychedelic Stud4: 4–15.
14.
GreerGTolbertR (1986) Subjective reports of the effects of MDMA in a clinical setting. J Psychoact Drugs18: 319–327.
15.
GuptaSK (2011) Intention-to-treat concept: A review. Perspect Clin Res2: 109–112.
16.
HakeHSDavisJWoodRR, et al. (2019) 3,4-methylenedioxymethamphetamine (MDMA) impairs the extinction and reconsolidation of fear memory in rats. Physiol Behav199: 343–350.
17.
Hall-ClarkBSawyerBGolikA, et al. (2016) Racial/ethnic differences in symptoms of posttraumatic stress disorder. Curr Psychiatry Rev12: 124–138.
18.
HarrisYGorelickPHSamuelsP, et al. (1996) Why African Americans may not be participating in clinical trials. J Natl Med Assoc88: 630–634.
19.
HartogsohnI (2016) Set and setting, psychedelics and the placebo response: An extra-pharmacological perspective on psychopharmacology. J Psychopharmacol30: 1259–1267.
HughesJLCamdenAAYangchenT (2016) Rethinking and updating demographic questions: Guidance to improve descriptions of research samples. Psi Chi J Psychol Res21: 138–151.
22.
IBM Corp. (2020) IBM SPSS Statistics for Windows, Version 27.0. Armonk, NY: IBM Corp.
23.
JacobsonNSTruaxP (1991) Clinical significance: A statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol59: 12–19.
24.
JeromeLFeducciaAAWangJB, et al. (2020) Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: A longitudinal pooled analysis of six phase 2 trials. Psychopharmacology237: 2485–2497.
25.
JohnsonMWRichardsWAGriffithsRR (2008) Human hallucinogen research: Guidelines for safety. J Psychopharmacol22: 603–620.
26.
KesslerRCChiuWTDemlerO, et al. (2005) Prevalence, severity, and comorbidity of twelve-month DSM-IV disorders in the National Comorbidity Survey Replication (NCS-R). Arch Gen Psychiatry62: 617–627.
27.
KiselySAlichniewiczKKBlackEB, et al. (2017) The prevalence of depression and anxiety disorders in indigenous people of the Americas: A systematic review and meta-analysis. J Psychiatric Res84: 137–152.
28.
KrystalJHDavisLLNeylanTC, et al. (2017) It is time to address the crisis in the pharmacotherapy of posttraumatic stress disorder: A consensus statement of the PTSD psychopharmacology working group. Biol Psychiatry82: e51–e59.
29.
LeBouthillierDMMcMillanKAThibodeauMA, et al. (2015) Types and number of traumas associated with suicidal ideation and suicide attempts in PTSD: Findings from a US nationally representative sample. J Trauma Stress28: 183–190.
30.
LesterKArtzCResickPA, et al. (2010) Impact of race on early treatment termination and outcomes in posttraumatic stress disorder treatment. J Consult Clin Psychol78: 480–489.
31.
Ma-KellamsC (2014) Cross-cultural differences in somatic awareness and interoceptive accuracy: A review of the literature and directions for future research. Front Psychol5: 1379.
32.
McClendonJDeanKEGalovskiT (2020) Addressing diversity in PTSD treatment: Disparities in treatment engagement and outcome among patients of color. Curr Treat Options Psychiatry7: 275–290.
33.
MichaelsTIPurdonJCollinsA, et al. (2018) Inclusion of people of color in psychedelic assisted psychotherapy: A review of the literature. BMC Psychiatry18: 245.
34.
MitchellJMBogenschutzMLiliensteinA, et al. (2021) MDMA-assisted therapy for severe PTSD: A randomized, double-blind, placebo-controlled phase 3 study. Nat Med27: 1025–1033.
MithoeferMCFeducciaAAJeromeL, et al. (2019) MDMA-assisted psychotherapy for treatment of PTSD: Study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology236: 2735–2745.
37.
NardouRLewisEMRothhaasR, et al. (2019) Oxytocin-dependent reopening of a social reward learning critical period with MDMA. Nature569: 116–120.
38.
National Institutes of Health (1994) NIH guidelines on the inclusion of women and minorities as subjects in clinical research. Fed Regist59: 1408–1413.
39.
Neitzke-SpruillL (2020) Race as a component of set and setting: How experiences of race can influence psychedelic experiences. J Psychedelic Stud4: 51–60.
40.
PagottoLFMendlowiczMVCoutinhoES, et al. (2015) The impact of posttraumatic symptoms and comorbid mental disorders on the health-related quality of life in treatment-seeking PTSD patients. Compr Psychiatry58: 68–73.
41.
RiggKK (2017) Motivations for using MDMA (ecstasy/molly) among African Americans: Implications for prevention and harm-reduction programs. J Psychoact Drugs49: 192–200.
42.
RiggKKLawentalM (2018) Perceived risk associated with MDMA (ecstasy/molly) use among African Americans: What prevention and treatment providers should know. Subst Use Misuse53: 1076–1083.
43.
RobertsALGilmanSEBreslauJ, et al. (2011) Race/ethnic differences in exposure to traumatic events, development of post-traumatic stress disorder, and treatment-seeking for post-traumatic stress disorder in the United States. Psychol Med41: 71–83.
44.
RojasSMBilskySADuttonC, et al. (2017) Lifetime histories of PTSD, suicidal ideation, and suicide attempts in a nationally representative sample of adolescents: Examining indirect effects via the roles of family and peer social support. J Anxiety Disord49: 95–103.
45.
SmithMWSchnurrPPRosenheckRA, et al. (2005) Employment outcomes and PTSD symptom severity. Ment Health Serv Res7: 89–101.
46.
StraussDde la SalleSSloshowerJ, et al. (2021) Research abuses against people of colour and other vulnerable groups in early psychedelic research. J Med Ethics. Epub ahead of print 12 July 2021. DOI: 10.1136/medethics-2021-107262.
47.
StreinerDL (2002) The case of the missing data: Methods of dealing with dropouts and other research vagaries. Can J Psychiatry47: 68–75.
48.
SuiteDHLa BrilRPrimmA, et al. (2007) Beyond misdiagnosis, misunderstanding and mistrust: Relevance of the historical perspective in the medical and mental health treatment of people of color. J Natl Med Assoc99: 879–885.
49.
SumnallHRColeJCJeromeL (2006) The varieties of ecstatic experience: An exploration of the subjective experiences of ecstasy. J Psychopharmacol20: 670–682.
50.
Tortella-FeliuMFullanaMAPérez-VigilA, et al. (2019) Risk factors for posttraumatic stress disorder: An umbrella review of systematic reviews and meta-analyses. Neurosci Biobehav Rev107: 154–165.
51.
UnnebrinkKWindelerJ (2001) Intention-to-treat: Methods for dealing with missing values in clinical trials of progressively deteriorating diseases. Stat Med20: 3931–3946.
VizeliPLiechtiME (2017) Safety pharmacology of acute MDMA administration in healthy subjects. J Psychopharmacol31: 576–588.
54.
WagnerMTMithoeferMCMithoeferAT, et al. (2017) Therapeutic effect of increased openness: Investigating mechanism of action in MDMA-assisted psychotherapy. J Psychopharmacol31: 967–974.
55.
WangJLinJBedrosianLCokerA, et al. (2021) Scaling up: Multi-site open-label clinical trials of MDMA-assisted therapy for severe post-traumatic stress disorder. J Humanist Psychol. Epub ahead of print 23 June 2021. DOI: 10.1177/00221678211023663.
WeathersFWBovinMJLeeDJ, et al. (2018) The clinician-administered PTSD scale for DSM-5 (CAPS-5): Development and initial psychometric evaluation in military veterans. Psychol Assess30: 383–395.
58.
WilliamsMTLabateBC (2020) Diversity, equity, and access in psychedelic medicine. Journal of Psychedelic Stud4: 1–3.
59.
WilliamsMTMetzgerILeinsC, et al. (2018) Assessing racial trauma within a DSM-5 framework: The UConn Racial/Ethnic Stress & Trauma Survey. Pract Innov3: 242–260.
60.
WilliamsMTReedSAggarwalR (2020) Culturally informed research design issues in a study for MDMA-assisted psychotherapy for posttraumatic stress disorder. J Psychedelic Stud4: 40–50.
61.
ZlotnickCRodriguezBFWeisbergRB, et al. (2004) Chronicity in posttraumatic stress disorder and predictors of the course of posttraumatic stress disorder among primary care patients. J Nerv Ment Dis192: 153–159.
62.
ZoellnerLAFeenyNCFitzgibbonsLA, et al. (1999) Response of African American and Caucasian women to cognitive behavioral therapy for PTSD. Behav Ther30: 581–595.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
